Sign up to save your podcasts
Or
Share Season 2 Episode 4: Two interviews with Joao P. De Aquino, MD and Donovan Maust, MD on the impact of cannabis on OUD treatment, and benzodiazepine discontinuation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Season 2 Episode 4: Two interviews with Joao P. De Aquino, MD and Donovan Maust, MD on the impact of cannabis on OUD treatment, and benzodiazepine discontinuation
“Behind the Evidence” is the addiction medicine podcast of the Grayken Center for Addiction at Boston Medical Center, and a project of the Center’s free bimonthly newsletter Alcohol, Other Drugs, and Health: Current Evidence (AODH). This episode was recorded in June 2024 and features an interview with Joao P. De Aquino, MD on his article published in the American Journal of Drug and Alcohol Abuse: “The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.” And an interview with Donovan Maust, MD on his article in JAMA Network Open: “Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy.” Click the following links to read AODH’s summaries of Dr De Aquino and Dr. Maust’s articles.
Also discussed: Christine PJ, Lodi S, Hsu HE, et al. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024;119(7):1313-1321.
Hosts: Honora L. Englander, MD and Marc R. Larochelle, MD
Production: Raquel Silveira, MBA
Editing: Casy Calver, PhD
Music and cover art: Mary Tomanovich, MA
Miriam Komaromy, MD is the Medical Director of the Grayken Center for Addiction, and co-Editor-in-Chief of AODH, together with David Fiellin, MD.
Learn more about AODH and subscribe for free at www.aodhealth.org
“Behind the Evidence” is supported by the Grayken Center for Addiction at Boston Medical Center. It is intended for educational purposes only, and should not be considered medical advice. The views expressed here are our own, and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.
View all episodes
By AOD Health“Behind the Evidence” is the addiction medicine podcast of the Grayken Center for Addiction at Boston Medical Center, and a project of the Center’s free bimonthly newsletter Alcohol, Other Drugs, and Health: Current Evidence (AODH). This episode was recorded in June 2024 and features an interview with Joao P. De Aquino, MD on his article published in the American Journal of Drug and Alcohol Abuse: “The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies.” And an interview with Donovan Maust, MD on his article in JAMA Network Open: “Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy.” Click the following links to read AODH’s summaries of Dr De Aquino and Dr. Maust’s articles.
Also discussed: Christine PJ, Lodi S, Hsu HE, et al. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024;119(7):1313-1321.
Hosts: Honora L. Englander, MD and Marc R. Larochelle, MD
Production: Raquel Silveira, MBA
Editing: Casy Calver, PhD
Music and cover art: Mary Tomanovich, MA
Miriam Komaromy, MD is the Medical Director of the Grayken Center for Addiction, and co-Editor-in-Chief of AODH, together with David Fiellin, MD.
Learn more about AODH and subscribe for free at www.aodhealth.org
“Behind the Evidence” is supported by the Grayken Center for Addiction at Boston Medical Center. It is intended for educational purposes only, and should not be considered medical advice. The views expressed here are our own, and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.